These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 7545721

  • 1. Endocrine therapy for benign prostatic hyperplasia in the 90's.
    Ekman P.
    J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological treatment of benign prostatic hyperplasia with finasteride: a clinical review.
    Ekman P.
    Arch Esp Urol; 1994 Nov; 47(9):883-7; discussion 887-8. PubMed ID: 7530944
    [Abstract] [Full Text] [Related]

  • 3. [Finasteride in the treatment of benign prostatic hypertrophy].
    Ekman P.
    J Urol (Paris); 1993 Nov; 99(6):299-302. PubMed ID: 7516372
    [Abstract] [Full Text] [Related]

  • 4. Finasteride in the treatment of benign prostatic hyperplasia.
    Ekman P, Andersen JT, Wolf H.
    Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328
    [Abstract] [Full Text] [Related]

  • 5. 5alpha-reductase inhibitors/finasteride.
    Stoner E.
    Prostate Suppl; 1996 Mar; 6():82-7. PubMed ID: 8630236
    [Abstract] [Full Text] [Related]

  • 6. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 7. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
    Radlmaier A, Eickenberg HU, Fletcher MS, Fourcade RO, Reis Santos JM, van Aubel OG, Bono AV.
    Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703
    [Abstract] [Full Text] [Related]

  • 8. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 9. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
    Tveter KJ, Beisland HO, Andersen JT, Wolf H, Ekman P, Johansson JE, Kontturi M, Lehtonen T.
    Tidsskr Nor Laegeforen; 1996 Nov 10; 116(27):3226-30. PubMed ID: 9011975
    [Abstract] [Full Text] [Related]

  • 10. [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
    Andersen JT, Wolf H, Ekman P, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K.
    Ugeskr Laeger; 1996 Sep 02; 158(36):5030-5. PubMed ID: 8928243
    [Abstract] [Full Text] [Related]

  • 11. [Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
    Hausmann R, Thalmann G, Reich O, Steif CG.
    Aktuelle Urol; 2004 Sep 02; 35(5):339-42. PubMed ID: 15383991
    [No Abstract] [Full Text] [Related]

  • 12. Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study.
    Lukkarinen O, Lehtonen T, Talja M, Lundstedt S, Tiitinen J, Taari K.
    Ann Chir Gynaecol; 1999 Sep 02; 88(4):299-303. PubMed ID: 10661828
    [Abstract] [Full Text] [Related]

  • 13. [New prospective therapy for benign prostatic hyperplasia with finasteride].
    Miano L, Manieri C, Paradiso Galatioto G, Vicentini C.
    Riv Eur Sci Med Farmacol; 1993 Sep 02; 15(2):111-9. PubMed ID: 7513437
    [Abstract] [Full Text] [Related]

  • 14. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
    Djavan B, McConnell J.
    Wien Med Wochenschr; 1996 Sep 02; 146(8):165-8. PubMed ID: 8767401
    [Abstract] [Full Text] [Related]

  • 15. The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment.
    Hill M, Petrik R, Hampl R, Stárka L.
    Horm Metab Res; 1996 Oct 02; 28(10):562-4. PubMed ID: 8934217
    [Abstract] [Full Text] [Related]

  • 16. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK, Ross M, Tate R, Chisholm GD.
    Clin Endocrinol (Oxf); 1997 Feb 02; 46(2):137-44. PubMed ID: 9135694
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of men on finasteride.
    Gormley GJ.
    Semin Urol Oncol; 1996 Aug 02; 14(3):139-44. PubMed ID: 8865475
    [Abstract] [Full Text] [Related]

  • 18. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS.
    Urology; 2004 Sep 02; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [Abstract] [Full Text] [Related]

  • 19. Medical management of benign prostatic hyperplasia: a review.
    Magoha GA.
    East Afr Med J; 1996 Jul 02; 73(7):453-6. PubMed ID: 8918007
    [Abstract] [Full Text] [Related]

  • 20. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
    Shibata Y, Fukabori Y, Ito K, Suzuki K, Yamanaka H.
    J Urol; 2001 Jan 02; 165(1):289-93. PubMed ID: 11125427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.